Side Effect Registry Immuno-Oncology

Side Effect Registry Immuno-Oncology

SERIO is a registry for adverse events of immunotherapies (immune-related adverse events, irAE): The aim of SERIO is to collect rare, complex and therapy-refractory cases to obtain knowledge for better side effect management and eventually be able to understand pathogenesis and predict side effects also in special patients (i.e. with autoimmune disease or solid organ transplant).

Myositis
Arthritis
Arthritis
Lichen ruber
Lichen ruber
Pneumonitis
Pneumonitis

Case of the Month

46-year old patient with prolonged irHepatitis and thrombopenia

Medical history
1
Melanoma of the skin stage IV M1c (AJCC 2017)
04/2007 Superficial spreading melanoma, nuchal left, Breslow 4,0 mm
02/2010 Naevoid melanoma, left abdomen, Breslow 3,0 mm
10/2018 Subcutaneous, nodal, pulmonary metastases
Oncological therapy
  •  04/2007 SNB (0/3)
  •  07/2007 – 07/2009 Interferon-alpha 3x3 Mio IE s.c./week
  • 11/2018 -11/2019 Immunotherapy with ipilimumab/pembrolizumab (4 cycles), followed by pembrolizumab
  • 11/2019-12/2019 BRAF/MEK inihibitior therapy with dabrafenib/trametinib
  • 12/2019-02/2020 BRAF/MEK inihibitior therapy with encorafenib/binimetinib
Immune related adverse event

3 months after initiation of the immunotherapy (IT) the patient experienced a hypophysitis that was substituted with hydrocortisone. 5 months after initiation she presented with an irGastritis with a concomittant Addison crisis. Subsequently she had progressive disease and was switched to dabrafenib/trametinib. 12 months after start of IT and one month after start of BRAF/MEK inihibitor therapy she presented with sinus bradycardia, pyrexia and again Addison crisis. Dabrafenib/trametinib was replaced by encorafenib/binimetinib. Another 3 months later she developed CTCAE grade 3 irHepatitis with histological confirmation. Prednisolone was initiated at 1 mg/kg body weight and transaminases decreased. However, on tapering they increase up to 1987 U/l ALT and 1496 U/l AST. Bilirubin was measured up to 21,6 mg/dl.

 

 

How did we proceed?

Prednisiolone was increased to 1000 mg/day, mycophenolate mofetil (MMF 500 mg 1-0-1)  and infliximab were added. Supportive drugs included rifampicin 150 mg (1-0-0) and konakion.

Could we continue with the immunotherapy?

Since she was progressive under immunotherapy no attempt to rechallenge was undertaken. After recovery of irHepatitis BRAF/MEK Inhibitor therapy with vemurafenib/cobimetinib was induced.

Our conclusion

In general, irHepatitis is common (7-33%) and can be fatal. Thrombopenia is rare (1.2-4.7%) and can mostly be well-managed. Sequential therapy with immunotherapy and subsequent BRAF/MEK Inhibitor theapy may lead to new complex side effect profiles (Dimitriou et al. J Immunother, 2018) as in this patient with sinus bradycardia that could not clearly be attributed to any specific drug. Escalation of immunosuppresion with MMF and infliximab worked well to treat irHepatitis in this patient.

54-year old male patient with rheumatic irAE

Medical history
1
Melanoma of the skin, stage IV M1b (AJCC2017)
07/2016 superficial spreading melanoma, thoracic left
09/2016 lymph node dissection, left axilla
11/2018 distant metastases: bipulmonary, pancreatic and lymph node metastases
Oncological therapy
  • 10/2016 – 08/2018 interferon-alpha 3 subcutaneous injections / week
  • 12/2018 initiation of immunotherapy with 4 cycles of ipilimumab and pembrolizumab, followed by pembrolizumab
Immune related adverse event

20 weeks after initiation of the immunotherapy the patient showed joint swelling and pain accompanied by morning stiffness of both knees. A therapy with corticosteroids was started. After an initial improvement of the symptoms and therefore the continuation of the immunotherapy, the joint effusion returned with increasing leg edemas and joint pain. After ruling out another cause of the symptoms (such as chronic heart insufficiency, thrombosis, erysipelas, bacterial joint infection) we diagnosed an immune related oligoarthritis.

Arthritis
Arthritis
How did we proceed?

Due to the corticosteroid-refractory course of the symptoms an onetime infusion with infliximab was given with a significant improvement.

Could we continue with the immunotherapy?

Due to returning symptoms after rechallenging with immunotherapy, we decided to discontinue the therapy. Fortunately the patient is in a complete response.  

Our conclusion

In general inflammatory arthritis after immune checkpoint blockade are uncommon (0,7%-5,5%) (Buder-Bakhaya et al. Cancer Immunol., Immunother. 2018 ; Le Burel et al. Eur J. Cancer 2017), but can develop a persistence of inflammation even after cessation of immunotherapy (Calabrese, L. H. et al. Nature Reviews. Rheumatology 2018). In mild courses immunotherapy can be reinitiated. However, in this case due to the recurrence of the irAE a discontinuation was necessary. 

60-year old female patient with nephrological irAE

Patient medical history
1
Melanoma of the skin stage IV M1c (AJCC 2017)
02/2005 superficial spreading melanoma, BRAF V600E mutated, right upper arm
03/2005 lymph node dissection, right axilla
02/2019 Distant metastases: bipulmonary, hepatic, splenic, bone and lymph node metastases
2
Medical history
10/2016 breast cancer of the left mamma (triple-negative, cT2, cN1) › surgery, radiation, adjuvant chemotherapy arterial hypertension hypothyroidism
arterial hypertension
hypothyroidism
Oncological therapy
  • 02/2019 initiation of immunotherapy with ipilimumab and pembrolizumab
Immune related adverse event

4 weeks after the initiation of immunotherapy the patient showed an interstitial nephritis. With the creatinine levels pictured below:

Diagram 1: creatinine-level (mg/dl)
How did we proceed?

Systemic steroids were given with a rapid improvement.

Could we continue the immunotherapy?

Immunotherapy was stopped and therapy changed to BRAF/MEK-inhibitor treatment.

Our Conclusion

In general nephrological irAE after immune checkpoint blockade are rare (1%-7%) (Heinzerling et al. Dtsch Arztebl Int 2019) but mostly quickly reversible. Often immunotherapy can be reinitiated. However, in this case the therapy was changed to BRAF/MEK-inhibitors.

Who we are

SERIO was originally initiated by dermatooncologists at the University Hospital of Erlangen in 2011 with the first documented case dating back to 2009. We are a certified cancer center and home to the German center of Immunotherapy (DZI). There was soon an intensive collaboration with endocrinologists, cardiologists and gastroenterologists that led to our interdisciplinary tox-board. We have also continuously collaborated within the Working Group Dermatooncolgy (ADO) to conduct projects, share experiences and gain new insights. More than 1000 cases of rare complex or very severe side effects from five countries were collected in a period of almost 10 years. We now host an online register in cooperation with the Paul-Ehrlich Institute. Today, we are cooperating with side effect specialists all over the world and hope to improve side effect management for cancer patients.

SERIO is there to help physicians manage side effects and obtain better knowledge on side effects induced by immunotherapy.

What we do 

  • Collect and analyze cases of rare, complex, severe and therapy-refractory side effects induced by immunotherapy
  • Give recommendations for treating physicians confronted with difficult irAE
  • Conduct research and support for people conducting research with regard to irAE